FDA GLP-1 vision-loss warning: what Canadian patients on weight-loss and diabetes drugs need to know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

The US Food and Drug Administration (FDA) announced on November 10, 2026 that every GLP-1 receptor agonist (GLP-1 RA) sold in the United States must add a warning about non-arteritic anterior ischemic optic neuropathy (NAION) to its labelling, citing an analysis of more than 125 clinical trials that found the condition in roughly six of every 100,000 patients who took a GLP-1 for at least one year. The affected drugs include semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for weight management, and as the oral tablet Rybelsus), as well as tirzepatide (sold in the US as Zepbound and Mounjaro; Mounjaro is approved in Canada). For Canadians, the immediate question is whether Health Canada will follow with its own labelling requirement. The answer is: not yet, but a formal safety review is already underway.

Last month, Health Canada announced it had identified a potential safety signal linking Ozempic, Rybelsus, and Wegovy to NAION and opened a review under its MedEffect Canada program. The findings have not been published. Canada operates under its own regulatory framework, separate from the FDA, and Health Canada sets labelling standards independently. Until Health Canada concludes its review and issues a decision, Canadian product labels for these drugs do not carry the NAION warning that US labels will now require. Canadian patients on any GLP-1 drug should be aware of the symptoms described below and discuss their individual risk with their prescriber, but they should not stop medication without medical guidance.

What this means in Canada

NAION is a condition in which blood flow to the optic nerve is reduced, causing sudden, painless, and potentially permanent vision loss in one or both eyes. Symptoms include blurred vision, blind spots, and distorted colour perception. The FDA's label change applies to all GLP-1 RAs approved in the US, including semaglutide, tirzepatide, liraglutide (sold in Canada as Victoza for diabetes and Saxenda for weight management), and dulaglutide (Trulicity). Health Canada's current safety review covers semaglutide products specifically; whether it will expand to the full drug class is not yet stated.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a position statement on GLP-1s and NAION risk. The SOGC has previously addressed GLP-1 use in the context of polycystic ovary syndrome and metabolic health, but no guidance specific to this ocular risk has been published as of November 2026.

On provincial coverage: semaglutide for type 2 diabetes (Ozempic) is listed on most provincial formularies, including Ontario's Ontario Drug Benefit (ODB) program, Quebec's RAMQ, British Columbia's PharmaCare, and Alberta's Alberta Health Care Insurance Plan (AHCIP) drug benefit, though criteria vary. Wegovy for obesity is covered far more narrowly. Most provincial plans do not yet list Wegovy as a standard benefit, meaning many patients pay out of pocket or through private insurance. Generic semaglutide has recently become available in Canada, which may affect formulary listings going forward. Patients uncertain about their coverage should check directly with their provincial drug plan or pharmacist.

Canadian telehealth platforms that prescribe GLP-1 drugs include Felix, Maple, and Science & Humans (scienceandhumans.com). Patients using these services should receive the same standard of care as in-person prescribers and should be informed of emerging safety signals. US-based platforms such as Hone Health, Midi, and Winona do not serve Canadian patients and are not subject to Health Canada oversight.

What changed and why it matters

The FDA's decision follows a 2024 study and subsequent FDA-conducted trials that examined the NAION signal. An analysis of data from more than 125 clinical trials found approximately six NAION cases per 100,000 patient-years of GLP-1 use. The FDA also reviewed spontaneous reports in its adverse-event database and concluded there is a "potential increased risk of rare NAION events in patients taking GLP-1 RAs." The agency stopped short of calling the link causal, using the phrase "potential increased risk" throughout its safety communication.

NAION is not new to ophthalmology. It is the most common acute optic nerve disease in adults over 50 and is associated with pre-existing conditions including diabetes, hypertension, obstructive sleep apnea, and a structurally small optic disc. Because many patients on GLP-1 drugs have type 2 diabetes or obesity, both of which independently raise NAION risk, isolating the drug's contribution is methodologically difficult. The FDA acknowledged the underlying cause of the association is unknown.

The absolute rate, six per 100,000 over a year or more of use, is low. For context, the background rate of NAION in the general population is estimated at two to ten per 100,000 per year, according to the American Academy of Ophthalmology. The signal is real enough to warrant a label warning, but it does not change the overall benefit-risk profile that led to these drugs' approvals for diabetes and obesity management.

What Canadian patients should know

If you are currently taking a GLP-1 drug, the practical steps are straightforward. Do not stop your medication based on this news alone. The cardiovascular, glycemic, and weight-management benefits of these drugs are well-documented, and abrupt discontinuation carries its own risks, particularly for patients with type 2 diabetes.

Tell your prescriber if you notice any sudden change in vision, including blurring in one eye, a new blind spot, or colour distortion. These symptoms warrant same-day or next-day assessment by an ophthalmologist or optometrist, not a wait-and-see approach. NAION typically presents suddenly and without pain, which is why patients may not initially connect it to a medication.

Patients with pre-existing risk factors for NAION, including diabetes, hypertension, a history of sleep apnea, or a prior episode of NAION in the other eye, should specifically raise this new safety signal with their prescriber at their next appointment. The conversation does not need to be urgent unless you have visual symptoms.

Patients in provinces with limited ophthalmology access, including many rural areas of British Columbia, Saskatchewan, and the Atlantic provinces, should ask their family physician or nurse practitioner about referral pathways before any symptoms arise.

Limitations and open questions

Health Canada has not yet published the findings of its NAION safety review for semaglutide products, and it has not announced whether it will extend the review to other GLP-1 drugs such as tirzepatide (Mounjaro) or liraglutide (Victoza, Saxenda). The timeline for a Health Canada decision is not public.

The causal mechanism is unknown. It is not clear whether NAION risk is a class effect of all GLP-1 RAs, specific to semaglutide, or driven by rapid weight loss or blood-pressure changes that accompany GLP-1 therapy rather than the drug itself. The 125-trial analysis was not a randomized controlled trial designed to detect ocular outcomes; it was a post-hoc signal-detection exercise.

Long-term data beyond one year of GLP-1 use and NAION incidence are limited. The SOGC has not issued guidance. The Canadian Ophthalmological Society has not issued a statement as of this writing. These are gaps that ongoing pharmacovigilance, including Health Canada's MedEffect review, is meant to address.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.